文献速递血液净化与透析肾血管病与高血压

多族裔透析患者钙化生物标志物与亚临床血管病变及死亡率的关联

Calcification Biomarkers, Subclinical Vascular Disease, and Mortality Among Multiethnic Dialysis Patients.
PubMed 文献 · Kidney Int Rep · 2020-08-06

在391例新发血液透析患者中,评估FGF23、dp-ucMGP、胎球蛋白A和OPG与冠状动脉钙化(CAC)、血管僵硬度和全因死亡率的关联。结果显示OPG和FGF23与CAC患病率轻度相关,OPG与基线PWV相关,FGF23与随访PWV较低相关,但dp-ucMGP和胎球蛋白A无关联,且所有标志物均与死亡率无关。

要点

  • OPG每升高5 pmol/L,CAC患病率增加1.09倍(95%CI 1.01-1.17)。
  • FGF23每升高100 log RU/ml,CAC患病率增加1.12倍(95%CI 1.02-1.34)。
  • 钙化生物标志物与亚临床血管病变关联较弱,且均不预测死亡。

核心结论

  • 在新发多族裔血液透析人群中,循环钙化生物标志物与亚临床心血管疾病仅呈轻度关联,且均与死亡率无关。

研究设计与样本

  • PACE研究纳入391例新发血液透析患者,平均年龄55岁,40%女性,72%非裔美国人,58%患糖尿病。

主要发现

  • OPG和FGF23与CAC患病率独立相关,OPG与基线PWV较高相关,FGF23与随访期间PWV较低相关。
  • dp-ucMGP和胎球蛋白A与CAC或血管僵硬度均无关联。
  • 调整后,所有循环生物标志物均与死亡风险无关。

关键数值与推荐

  • CAC采用Agatston钙化标准评估,血管僵硬度用脉搏波速度(PWV)在4次访视中测量。

临床怎么用

  • 钙化生物标志物目前不足以作为透析患者血管病变或死亡风险的独立预测工具,需更大规模研究验证。

局限性

  • 研究为观察性设计,样本量有限,结果需在更大规模、多样化透析人群中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vascular calcification and stiffness are associated with higher mortality and cardiovascular disease in hemodialysis patients, but the underlying mechanism is not well elucidated and previous studies have been contradictory. We sought to determine the association of circulating calcification biomarkers with calcification, stiffness, and mortality in a multiethnic incident dialysis population. METHODS: Among 391 incident hemodialysis participants enrolled in the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study, we examined the cross-sectional associations of baseline fibroblast growth factor 23 (FGF23), desphospho-uncarboxylated matrix Gla protein (dp-ucMGP), fetuin-A, and osteoprotegerin (OPG) according to total coronary artery calcium score (CAC, using the Agatston calcification criteria) at baseline, vascular stiffness (pulse wave velocity [PWV]) over 4 study visits, and all-cause mortality. RESULTS: Patients' mean age was 55 years; 40% were female, 72% were African American, and 58% had diabetes. Higher OPG and FGF23 were associated with a 1.09-fold (per 5-pmol/l increase in OPG; 95% confidence interval [CI]: 1.01-1.17) and 1.12-fold (per increase of 100 log RU/ml in FGF23; 95% CI: 1.02‒1.34) higher prevalence of CAC, independent of demographics, comorbidities, dialysis factors, and serum klotho levels. Higher OPG was associated with higher baseline PWV. Higher FGF23 was associated with lower PWV over follow-up. dp-ucMGP and fetuin-A were not associated with either CAC or vascular stiffness. After adjustment, circulating biomarkers were not associated with mortality risk. CONCLUSION: Several circulating calcification biomarkers were only modestly associated with subclinical cardiovascular disease in an incident multiethnic hemodialysis population; none were associated with mortality. Understanding whether these associations persist in larger, diverse hemodialysis populations is warranted before planning trials.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Fitzpatrick J, Kim ED, Sozio SM, et al. Calcification Biomarkers, Subclinical Vascular Disease, and Mortality Among Multiethnic Dialysis Patients. Kidney Int Rep. 2020. PMID: 33102965. doi:10.1016/j.ekir.2020.07.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。